InMed Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED
| For the Three Months Ended | ||
|---|---|---|
| September 30, | ||
| 2024 | 2023 | |
| $ | $ | |
| Sales | 1,264,638 | 901,862 |
| Cost of sales | 771,225 | 880,620 |
| Gross profit | 493,413 | 21,242 |
| Operating Expenses | ||
| Research and development and patents | 771,180 | 1,292,093 |
| General and administrative | 1,421,926 | 1,298,731 |
| Amortization and depreciation | 54,579 | 54,832 |
| Foreign Exchange (Gain) Loss | (19,310) | 48,457 |
| Total operating expenses | 2,228,375 | 2,694,113 |
| Other Income (Expense) | ||
| Interest and other income | 57,094 | 136,043 |
| Loss before income tax expense | (1,677,868) | (2,536,828) |
| Income tax expense | - | - |
| Net loss | (1,677,868) | (2,536,828) |
| Net loss per share | ||
| Basic and diluted | (2.71) | (15.24) |
| Weighted average outstanding Common Shares | ||
| Basic and diluted | 620,127 | 166,410 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.